Cannabidiol (CBD) represents a promising therapeutic tool for treating cannabis use disorder (CUD). This study aimed to evaluate the effects of CBD on the behavioural and gene expression alterations induced by spontaneous cannabinoid withdrawal.
Introduction
Cannabis preparations, such as hashish and marijuana, are the most commonly used illicit drugs worldwide. The data available suggest that their consumption will continue to rise in coming years, representing a serious public health problem (Volkow et al., 2014) . Approximately 24% of patients initiating treatment for substance abuse are diagnosed with cannabis use disorder (CUD) (Danovitch and Gorelick, 2012) . According to the latest World Drug Report (United Nations Office on Drugs and Crime, 2016), around 182.5 million people used cannabis in 2016.
To date, neither the European Medicine Agency nor the US Food and Drug Administration have approved any medications for treating CUD; however, different pharmacological approaches have been developed. These fall into two main categories: medications that attenuate symptoms of cannabis withdrawal and/or those that reduce subjective and reinforcing effects of cannabis (for a recent review, see Copeland and Pokorski, 2016) . About half the patients treated for CUD report symptoms of a withdrawal syndrome. As these symptoms can serve as a negative reinforcement for relapse to cannabis use in individuals trying to abstain (Levin et al., 2010) , cannabis withdrawal should be a focus of treatment. Previous clinical trials have evaluated the therapeutic usefulness of different pharmacological approaches for managing cannabis withdrawal and modulating the reinforcing effects and craving for cannabis, with inconsistent results (Danovitch and Gorelick, 2012) . However, the overall clinical outcome in the treatment arms of randomized trials is poor, and fewer than 20% of participants achieve long-term abstinence (Stephens and Roffman, 2006) . In spite of the animal models developed to analyse cannabis abuse liability (Justinova et al., 2005) , limited knowledge of the neurochemical mechanisms underlying CUD may contribute, at least in part, to the low efficacy of the medications evaluated to date. Therefore, it is necessary to invest effort and resources into identifying new drugs that, alone or in combination, may improve the efficacy of CUD treatment.
Recent clinical data suggest that cannabidiol (CBD), one of the main constituents of the Cannabis sativa plant, may hold promise as a therapeutic tool for managing CUD. Our group has recently shown that unlike Δ 9 -tetrahydrocannabinol (THC), CBD is devoid of rewarding psychotropic properties (Manzanares et al., 2016) . Studies in animal models have shown that CBD presents anxiolytic (for a recent review, see Blessing et al., 2015) , antidepressant (Zanelati et al., 2010; Schiavon et al., 2016) and antipsychotic properties (Zuardi et al., 1995; Leweke et al., 2012) . Although the exact mechanisms underlying these effects remain unclear (Campos et al., 2012b) , some authors have posited that CBD modulates the function of more than 65 targets in the CNS (Ibeas Bih et al., 2015) , including cannabinoid receptors (CB 1 and CB 2 ) and GPR55, the vanilloid receptor TRPV1, the 5-HT 1A receptor (Bisogno et al., 2001; Russo et al., 2005; Ryberg et al., 2007; Thomas et al., 2007; Campos et al., 2012a) , the anandamide (AEA)-hydrolysing enzyme [fatty acid amide hydrolase (FAAH)] and the adenosine transporter (Carrier et al., 2006; Massi et al., 2008) . However, additional studies are needed to fully determine CBD's target engagement profile.
Previous clinical results point to the therapeutic usefulness of combining CBD with THC as a 'cannabinoid replacement therapy' to modulate cannabinoid withdrawal (Allsop et al., 2015) . Combination therapy with THC plus CBD in an oromucosal spray (nabiximols or Sativex in the United States of America or European Union, respectively) shows some interesting therapeutic benefits. Indeed, a recent clinical trial demonstrated that nabiximols suppressed cannabis withdrawal symptoms and achieved successful retention in treatment (Allsop et al., 2014) . Two additional studies showed that Sativex produces a significant reduction in cannabis withdrawal score, craving and cannabis consumption levels (Trigo et al., 2016a; Trigo et al., 2016b) .
However, the presence of THC in nabiximols/Sativex preparations could be problematic, especially in (still unexplored) long-term treatment, since it may be associated with THC-related negative psychoactive effects. Thus, recent interest has turned to clinically evaluating CBD alone for managing CUD-related problems. Crippa et al. (2013) found that CBD monotherapy led to a rapid decrease in cannabis withdrawal symptoms. Another clinical study, comparing p.o. CBD alone versus placebo, found no difference between groups for cannabis-induced subjective effects (Haney et al., 2016) . These reports join a raft of ongoing clinical trials evaluating the effects of CBD alone for CUD (Mclean Hospital, NCT03102918), cannabis dependence (University College, London, NCT02044809), cannabis withdrawal (The University of New South Wales, NCT02083874) or smoked marijuana's (5.6% THC) subjective, reinforcing, cognitive and cardiovascular effects (National Institute on Drug Abuse, NCT01844687). In the context of this increasing interest in CBD for managing CUD, studies using animal models are crucial to providing information about the therapeutic potential of CBD and the underlying neurobiological mechanisms involved.
The objective of this study is to evaluate the effects of CBD on the spontaneous withdrawal induced by the repeated administration of the potent synthetic cannabinoid receptor agonist CP-55,940 (Devane et al., 1988; Wiley et al., 1995; Oliva et al., 2003; Aracil-Fernandez et al., 2013) in C57BL/6J mice. Motor activity (distance travelled in the open field test), withdrawal-related somatic signs (number of rearings, groomings, rubbings and jumpings evaluated in the open field test) and the anxiety-like response (light-dark box test) were assessed 12 h after the last administration of CP-55,940. Furthermore, gene expression analyses by realtime PCR were carried out to evaluate the changes induced by cannabinoid withdrawal in specific key targets involved in cannabinoid addiction and withdrawal (Romero et al., 1998; Corchero et al., 1999; Manzanares et al., 1999; Oliva et al., 2003 Oliva et al., , 2004 Lupica et al., 2004; Corchero et al., 2004a, b; Fattore et al., 2008; Aracil-Fernandez et al., 2013) , namely, TH in the ventral tegmental area (VTA), and the opioid μ receptor (Oprm1), CB 1 receptor (Cnr1) and CB 2 receptor (Cnr2) in the nucleus accumbens (NAcc). Briefly, TH is the ratelimiting enzyme for dopamine synthesis in the VTA, playing a pivotal role in the rewarding effects of cannabinoids. Similarly, the μ receptor in the NAcc plays a crucial role in the reinforcing actions of cannabinoid drugs, increasing the release of endogenous opioid peptides that in turn enhance the dopamine tone. Finally, CB 1 and CB 2 receptors directly modulate the neurobiological actions produced by the administration of cannabinoid compounds.
Methods

Mice
A total of 180 male C57BL/6J mice from Charles River (Lille, France) weighing 20-25 g were employed in this study, and were housed in groups of five per cage (40 × 25 × 22 cm) under controlled conditions (temperature, 23 ± 2°C; relative humidity, 60 ± 10%; and 12 h light/dark cycle, lights on from 08:00 to 20:00 h). One week after acclimatization to the animal room, behavioural analyses were initiated and performed by placing the home cage in the operant-task room during the development of conditioning experiments. All studies complied with the Spanish Royal Decree 53/2013, the Spanish Law 32/2007 and the European Union Directive of the 22nd of September 2010 (2010/63/UE) regulating the care of experimental animals, and were approved by the ethics committee of Miguel Hernandez University. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
Drugs
Cannabinoid CB 1 receptor agonist CP-55,940 ((À)-cis-3-(2-hydroxy-4-(1,1,dimethyl-heptyl)-phenyl)-trans-4(3-hydroxypropyl)cyclohexanol) obtained from Biogen (Madrid, Spain) was dissolved in ethanol : cremophor : saline (1:1:18) immediately before use and administered i.p. (0.5 mg·kg À1 every 12 h, for 7 days)
as described elsewhere (Aracil-Fernandez et al., 2013) . CBD, obtained from STI Pharmaceuticals (Essex, UK), was dissolved in ethanol : cremophor : saline (1:1:18) immediately before use to obtain the required doses (5, 10 and 20 mg·kg
À1
) and administered i.p. during spontaneous cannabinoid withdrawal 90 min before behavioural evaluation according to plasma and brain pharmacokinetic profiles (Deiana et al., 2012) .
Experimental design
Evaluation of CBD effects on CP-55,940-induced spontaneous cannabinoid withdrawal. In order to evaluate cannabinoid tolerance and withdrawal, the synthetic cannabinoid agonist CP-55,940 was employed as described previously (Oliva et al., 2003; Aracil-Fernandez et al., 2013) . Forty C57BL/6J male mice were injected with CP-55,940 (0.5 mg·kg À1 every 12 h, i.p.) and 10 mice with vehicle (ethanol : cremophor : saline; 1:1:18) for 7 days (schematic diagram displayed in Figure 1A ). Changes in rectal temperature and motor activity were measured during tolerance development (days 1, 3 and 7 
Evaluation of CBD effects on vehicle-treated animals.
Forty C57BL/6J male mice were injected with vehicle (ethanol : cremophor : saline; 1:1:18; twice a day every 12 h, i.p.) for 7 days (schematic diagram displayed in Figure 1B ) in order to study the effects of CBD alone. Changes in rectal temperature and motor activity were measured during
Figure 1
Experimental designs to induce and evaluate the spontaneous cannabinoid withdrawal (A) and analyse the effects of CBD administration in vehicle-treated animals (B).
treatment with vehicle (days 1, 3 and 7). On the day after the last vehicle administration, mice were randomly allocated to four experimental groups to be administered CBD (5, 10 and 20 mg·kg À1 , i.p., 10 mice per dose) or its corresponding vehicle, 90 min before the evaluation of motor activity and behavioural signs associated with abstinence (number of rearings, groomings, rubbings and jumpings) in a 15 min session. An additional set of 40 C57BL/6J male mice was evaluated after the last vehicle administration to study the effects of CBD treatment on anxiety-like behaviour, following the same randomization procedure to assign animals to the different treatment groups. All the behavioural paradigms (open field test to evaluate motor activity and somatic signs and light-dark box test to evaluate anxiety-like level) were made under blind conditions.
Assessment of tolerance to cannabinoid administration
Motor behaviour -open field test. On day 0, under baseline conditions and 60 min after the administration of CP-55,940 or vehicle on days 1, 3 and 7, the mice were placed into individual methacrylate boxes (25 × 25 × 25 cm), and their motor responses were evaluated according to distance travelled for 15 min. The assessment of motor activity was carried out by using the Spontaneous Motor Activity Recording and Tracking (SMART) programme by Panlab (Barcelona, Spain).
Rectal temperature. Rectal temperature was measured in each mouse using a lubricated digital thermistor probe (Panlab), inserted 1 cm into the rectum for 30 s. Rectal temperature was determined 30 min before and after each morning injection of CP-55,940 or vehicle during the tolerance period on days 1, 3 and 7.
Behavioural assessment after cannabinoid withdrawal
Behaviour in CP-55,940-induced spontaneous cannabinoid withdrawal and vehicle-treated animals was assessed by measuring motor activity; the number of rearings, groomings, rubbings, jumpings; and the anxiety-like behaviour on the day after the cessation of cannabinoid or vehicle treatment.
Motor activity and somatic expression. Twelve hours after cessation of treatment with CP-55,940 or vehicle, mice were placed into individual methacrylate boxes (25 × 25 × 25 cm). Ninety minutes after CBD (5, 10 and 20 mg·kg À1 ) or vehicle administration, mice behaviour was videotaped for 15 min, and the somatic signs associated with abstinence (number of rearings, groomings, rubbings and jumpings) were subsequently analysed from the recording. At the same time, motor responses were also evaluated by measuring the distance travelled by the mice for 15 min with the SMART programme (Panlab).
Light-dark box test.
To evaluate anxiety-like behaviour associated with cannabinoid withdrawal, 12 h after cessation of treatment with CP-55,940 or vehicle, mice were individually tested for 5 min in the light-dark box paradigm, 90 min after the administration of CBD (5, 10 and 20 mg·kg À1 ) or its corresponding vehicle. At the beginning of the session, the mice were placed in the tunnel facing the dark side. The number of transitions and the time spent on the light side were measured in each session.
Gene expression studies by real-time PCR
Relative gene expression analyses of TH in the VTA, and Oprm1, Cnr1 and Cnr2 in the NAcc, were carried out in vehicle-treated and CP-55,940-treated C57BL/6J mice employed to evaluate the effects of CBD on motor activity and somatic signs during CP-55,940-induced spontaneous cannabinoid withdrawal (see Figure 1A) . Briefly, mice were killed by cervical dislocation 150 min after CBD administration on day 8. Brains were removed from the skull and frozen over dry ice. Coronal sections (500 μm) containing the regions of interest were cut in a cryostat (À10°C) according to the Paxinos and Franklin atlas (Paxinos and Franklin, 2001) , mounted onto slides and stored at À80°C. Sections were microdissected following the method described by Palkovits (Palkovits, 1983 (Livak and Schmittgen, 2001 ).
Statistical analyses
Statistical analyses were performed using one-and two-way ANOVA with repeated measures (RM) when several time points are present, followed by the Student-Newman-Keul's test when comparing different experimental groups. Differences were considered significant if the probability of error was less than 5%. Data are presented as mean ± SEM. Sigmaplot 11 software (Systat software Inc., Chicago, IL, USA) was used for all statistical analyses. The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Table 1 presents all the statistical data included in the results section. P values < 0.05 were considered to indicate statistical significance.
Results
Development of tolerance induced by the administration of CP-55,940
The development of tolerance to cannabinoid administration was evaluated by measuring motor behaviour and rectal temperature. Two-way RM ANOVA revealed decreased motor activity in the CP-55,940-treated group on day 1 compared with the other days and with the vehicle-treated group only on day 1 [ Figure 2A ; treatment (P < 0.001), day (P = 0.016) and treatment × day interaction (P < 0.001)]. Two-way ANOVA showed that CP-55,940 administration significantly decreased rectal temperature in comparison with the vehicle-treated group on days 1 and 3, reaching similar temperatures to control mice on day 7 [ Figure 2B ; treatment (P < 0.001), day (P < 0.001) and treatment × day interaction (P < 0.001)].
Effects of CBD on increased motor activity and somatic signs induced by spontaneous cannabinoid withdrawal
The one-way ANOVA showed that CP-55,940 treatment cessation significantly increased motor activity and the number of rearings, rubbings and jumpings compared with vehicle-treated mice [ Figure 3A , motor activity (P < 0.001); Figure 3B , number of rearings (P < 0.001); Figure 3D , number of rubbings (P < 0.001); and Figure 3E , number of jumpings (P < 0.001)]. The administration of CBD fully blocked these parameters, which reached values similar to those found in the control group. On the other hand, the number of groomings after cannabinoid cessation decreased significantly compared with the control group. One-way ANOVA indicated that the CP-55,940 + CBD-treated group showed a normalization effect reaching a significant difference compared with the CP-55,940 + vehicle-treated group with the highest CBD dose ( Figure 3C , number of groomings, P < 0.001).
Effects of CBD on anxiogenic-like behaviour induced by spontaneous cannabinoid withdrawal
After CP-55,940 treatment, the one-way ANOVA revealed a significant decrease in the time spent in the light box ( Figure 4A , P < 0.001) and the number of transitions ( Figure 4B , P < 0.001) in the CP-55,940 + vehicle-treated group compared with the control group. The administration 
Effects of CBD on changes in the TH, Oprm1, Cnr1 and Cnr2 gene expression induced by spontaneous cannabinoid withdrawal
Changes in TH gene expression, and in Oprm1, Cnr1 and Cnr2 gene expressions, were measured in the VTA and in the NAcc Figure 5A , one-way ANOVA, P < 0.001) and Cnr2 gene expression ( Figure 5D , one-way ANOVA, P = 0.007), whereas it increased both Oprm1 ( Figure 5B , one-way ANOVA, P < 0.001) and Cnr1 gene expressions ( Figure 5C , one-way ANOVA, P < 0.001). The administration of CBD blocked the effects of cannabinoid withdrawal on TH, Oprm1, Cnr1 and Cnr2 gene expression. 
Evaluation of motor activity and rectal temperature during 7 days of vehicle administration
Distance travelled and rectal temperature variation (30 min before and after administration) was evaluated in the animals treated with vehicle. Motor activity progressively decreased from day 1 to day 7 in the open field ( Figure 6A , one-way ANOVA, P < 0.001) reflecting a habituation effect similar to that observed in the vehicle-treated animals represented in Figure 2 . With regard to rectal temperature, the vehicle group did not show any change between the evaluation days ( Figure 6B , one-way ANOVA, P = 0.209).
Effects of CBD on motor activity and somatic signs in vehicle-treated animals
CBD administration did not induce changes in the somatic signs displayed by the vehicle-treated animals (as assessed by one-way ANOVA) suggesting that the normalization effect achieved in CP-55,940-treated animals was specific [ Figure 7A , motor activity (P = 0.551); Figure 7B , number of rearings (P = 0.859); Figure 7C , number of groomings (P = 0.874); and Figure 7D , number of rubbings (P = 0.930)]. Figure 7 does not present the number of jumpings as vehicle-treated animals did not display this behaviour.
Effects of CBD on anxiety-like behaviour in vehicle-treated animals
Anxiety-like behaviour in vehicle-treated animals was reduced significantly after the administration of CBD (10 and 20 mg·kg À1 ), increasing the latency time in the light box ( Figure 8A , P = 0.007), whereas the number of transitions was similar between the different treatment groups ( Figure 8B , P = 0.240).
Discussion
The results of this study suggest that CBD is useful for alleviating the motor symptoms and anxiety-like behaviours associated with spontaneous withdrawal of the cannabinoid receptor agonist CP-55,940, with several observations supporting this assumption: (i) after cessation of treatment with CP-55,940, CBD normalized the increase in the distance travelled and the number of rearings, rubbings and jumpings, as well as the reduction in the number of groomings; (ii) mice receiving CBD showed greatly reduced anxiety-like behaviour associated with the cannabinoid withdrawal compared with controls; (iii) the administration of CBD also blocked the reduction in TH and Cnr2 gene expression in the VTA and NAcc, respectively, and the increase in Oprm1 and Cnr1 gene expression in the NAcc, induced by spontaneous cannabinoid withdrawal; and (iv) CBD did not modify the motor activity or the somatic signs (number of rearings, rubbings and groomings) displayed by non-abstinent mice but induced an anxiolytic-like effect in vehicle-treated animals.
The reduction in motor activity and rectal temperature found on day 1 after CP-55,940 administration returned to normal values on days 3 and 7 of treatment, respectively, indicating the development of tolerance. Subsequently, treatment with CP-55,940 was abruptly discontinued to generate a spontaneous withdrawal (without cannabinoid antagonist administration). This was characterized by a variety of behavioural manifestations, such as an increase in distance travelled, number of rearings, rubbings and jumpings, and anxiety-like behaviour, together with a decrease in the number of groomings. These results are in agreement with previous findings from our laboratory employing the same model of spontaneous cannabinoid withdrawal (Oliva et al., 2003; Aracil-Fernandez et al., 2013) .
The administration of CBD significantly affected the motor activity observed in mice during the spontaneous cannabinoid withdrawal, although this effect was only reached at the highest dose (20 mg·kg À1 ). In addition, all CBD doses tested (5, 10 and 20 mg·kg À1 ) blocked the increase in the number of rearings and reduced the significant increase in the number of rubbings and jumpings. The number of groomings decreased considerably during cannabinoid withdrawal, as described elsewhere (Cook et al., 1998) , but the highest dose (20 mg·kg À1 ) of CBD administered led to a significant increase in this behaviour. Interestingly, the effects
Figure 6
Assessment of motor activity and rectal temperature variations in mice injected i. of CBD on motor activity and somatic signs were specific to the CP.55,940-induced spontaneous withdrawal since its administration to vehicle-treated mice (animals not developing spontaneous cannabinoid withdrawal) did not induce any significant behavioural change. Moreover, mice experiencing cannabinoid withdrawal presented a high degree of anxiety Values from vehicle + CBD-treated mice that are significantly different (P < 0.05) from the control group (vehicle + vehicle) (one-way ANOVA followed by Student-Newman-Keul's test).
with a significant reduction in the time spent in the lighted box. All doses of CBD completely abolished this anxiogeniclike effect without affecting the number of transitions compared with the CP-55,940 + vehicle-treatment group. In addition, CBD also induced an anxiolytic-like effect in vehicletreated animals without modifying the number of transitions between the different treatment groups. The literature contains numerous reports supporting an anxiolytic effect for CBD; for a recent review, see Blessing et al. (2015) .
The results obtained in the present study suggest that under these experimental conditions, CBD significantly alleviates the most prominent behavioural symptoms associated with CP-55,940-induced spontaneous cannabinoid withdrawal. To our knowledge, this is the first study that has evaluated the effect of CBD on spontaneous cannabinoid withdrawal in an animal model and explored some of the underlying neurobiological mechanisms potentially involved. Although there is currently little clinical evidence for this treatment approach and especially for the effects of CBD alone, our results are consistent with some existing findings, such as those reported by Crippa et al. (2013) . Therefore, additional translational studies combining both clinical and basic perspectives are warranted to clarify the therapeutic potential of CBD for cannabinoid withdrawal symptoms. This experimental approximation will be crucial to the development of future pharmacological strategies for managing CUD at the clinical level.
Nowadays, it is well known that cannabis withdrawalsimilar to withdrawal from other drugs of abuse -decreases mesolimbic dopamine neuronal activity (Oleson and Cheer, 2012) . Indeed, cessation of THC treatment produced a reduction in the spontaneous firing rate of dopamine neurons in VTA similar to that observed with other addictive drugs (Diana et al., 1998) . Likewise, our group's present and past research clearly demonstrates that abrupt cessation of CP-55,940 treatment significantly decreases TH gene expression in VTA neurons (Oliva et al., 2003; Aracil-Fernandez et al., 2013) . Interestingly, CBD administration normalized this alteration, increasing the mRNA levels of TH in the VTA. In line with this result, a recent study from our laboratory also revealed that CBD modulates TH gene expression in animals exposed to EtOH under different behavioural paradigms (Viudez-Martinez et al., 2018) . The mechanisms that could be involved in these phenomena are still unknown, although several hypotheses have recently emerged regarding the effects of CBD on the mesolimbic dopamine system (Renard et al., 2017) . Indeed, one of the well-described CBD's mechanisms of action is the inhibition of FAAH, which in turn has been associated with TH modulation (Bosier et al., 2013) . Therefore, the supposed regulation of dopamine synthesis by means of CBD-mediated effects on TH gene expression could be involved in the alleviation of the effects of cannabinoid withdrawal.
There is evidence supporting the interaction between the endogenous opioid and cannabinoid systems (Corchero et al., 2004a) . Previous results demonstrated that cannabinoid administration increases the release of endogenous opioid peptides and opioid-related gene expression, mechanisms closely involved in the regulation of cannabinoid reinforcing actions (Manzanares et al., 1999; Corchero et al., 2004b) . Indeed, our results indicate that spontaneous withdrawal induced by interruption of cannabinoid receptor agonist administration significantly increased Oprm1 gene expression in the NAcc, and this effect was completely normalized by the administration of CBD. Interestingly, Kathmann et al. (2006) described the CBD-mediated allosteric modulation of the μ receptor by means of kinetic binding studies with [ 3 H]-DAMGO, although the observed effect only occurred at very high concentrations and cannot be expected to contribute to its in vivo action. In addition, CBD significantly downregulated Oprm1 in the NAcc, with this effect being accompanied by a reduction in EtOH consumption (Viudez-Martinez et al., 2018) . Thus, it is reasonable to suggest that the CBDmediated regulation of the μ receptor function could be involved in alleviating cannabinoid withdrawal symptoms, as well as those of opioid withdrawal, as proposed elsewhere (Hine et al., 1975a,b; Bhargava, 1976) .
In our study, as in previous reports (Oliva et al., 2003; Aracil-Fernandez et al., 2013) , Cnr1 gene expression was significantly up-regulated in the NAcc. Different authors have attributed this increase to a compensatory neuroadaptative response to down-regulation of cannabinoid receptors found after repeated treatment with a cannabinoid receptor agonist (Sim et al., 1996; Romero et al., 1998) . CBD reduced the Cnr1 up-regulation induced by spontaneous cannabinoid withdrawal. This result is also in agreement with CBDinduced reduction associated with a decrease in EtOH intake in C57BL/6J mice (Viudez-Martinez et al., 2018) . Previous studies suggested that CBD acts as a non-competitive allosteric modulator of the cannabinoid CB 1 receptor through the alteration of AEA hydrolysis by inhibiting its catabolic enzyme, FAAH (Bisogno et al., 2001; Laprairie et al., 2015) . Based on this assumption, it is tempting to hypothesize that the modification of the AEA concentrations could be related, at least in part, to the neurochemical changes induced by CBD and the modulation of the cannabinoid withdrawal syndrome. However, additional experiments are necessary to shed light on this matter.
Finally, previous studies have shown that the cannabinoid CB 2 receptor is involved in regulating addictive behaviours, suggesting that this target plays a pivotal role in modulating the reinforcing effects of cocaine, nicotine and alcohol (Aracil-Fernandez et al., 2012; Navarrete et al., 2013; Ortega-Alvaro et al., 2015) . However, there is very little information regarding the involvement of CB 2 receptors in cannabis addiction, or specifically in cannabis withdrawal. The realtime PCR analyses from the present study show for the first time that spontaneous cannabinoid withdrawal is linked to a significant Cnr2 down-regulation in the NAcc, although the underlying mechanisms have yet to be elucidated. As CBD up-regulates Cnr2 gene expression (Viudez-Martinez et al., 2018) , this normalization effect could be related to the improvement in cannabinoid withdrawal behavioural disturbances induced by the administration of CBD. There is controversy with regard to the pharmacological effect of CBD on CB 2 receptors, but a recent report points out that CBD acts as an allosteric modulator (Martinez-Pinilla et al., 2017) . Future studies are needed to better understand the interaction between CBD and CB 2 receptors.
In conclusion, the results of the present study provide unequivocal evidence for the efficacy of CBD to reduce the behavioural disturbances associated with CP-55,940-induced spontaneous cannabinoid withdrawal. Furthermore, the gene expression analyses of targets closely involved in the cannabinoid-related addictive actions and withdrawal (TH, Oprm1, Cnr1 and Cnr2) provide valuable information about the neurochemical processes that could be involved, at least in part, in the CBD-mediated regulation of cannabinoid withdrawal. Further studies are needed to evaluate the potential therapeutic actions of CBD for the clinical management of CUD and to elucidate the precise underlying neurobiological mechanisms involved.
